Category - Developments

Developments

FDA approves REGENXBIO gene therapy for pediatric spinal muscular atrophy

The FDA approved REGENXBIO’s (NASDAQ:RGNX) ZOLGENSMA for the treatment of spinal muscular atrophy (SMA) in pediatric patients who are less than two years of age. Caused by a genetic defect in the SMN1 gene, SMA is...

May 24, 2019

Developments

Neovasc reports positive two-year data for Reducer device

Neovasc (NASDAQ:NVNC) reported positive long term safety and efficacy data for its Reducer device in 50 patients suffering from refractory disabling angina. Neovasc’s Reducer relives angina symptoms by altering blood...

May 24, 2019

Developments

Iovance cervical cancer therapy gets FDA breakthrough designation

Iovance Biotherapeutics (NASDAQ:IOVA) LN-145 received FDA breakthrough therapy designation in recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy. Designed to...

May 24, 2019

Developments

Zenabis graduates to the TSX

Zenabis Global Inc. (TSXV:ZENA) received approval to list its common shares and outstanding listed common share purchase warrants on the TSX.

May 24, 2019

Developments

Canopy Growth acquires skincare and well-being company, This Works

Canopy Growth (TSX:WEED; NYSE: CGC) acquired This Works in an all-cash transaction for £43 million. British-based This Works offers a range of high-quality natural skincare and sleep solution products, including deep...

May 22, 2019

Developments

Brookline Capital in partnership with Arcadia Securities

Investment banker Brookline Capital Markets entered into a partnership with broker-dealer, Arcadia Securities. The transaction allows Brookline to capitalize on and expand its growing presence in the public capital...

May 22, 2019

Developments

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

BeyondSpring’s (NASDAQ:BYSI) abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 2019 conference May 18-22 in New...

May 21, 2019

Developments

Theralase receives patent notice of acceptance for PD compounds in China

The Chinese patent office granted Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) a notice of acceptance for its light activated photodynamic compounds (PDC) intended to safely and effectively destroy various cancers...

May 21, 2019

Developments

FDA accepts Abeona IND for CLN1 disease gene therapy

The FDA has accepted Abeona Therapeutics (NASDAQ:ABEO) IND application for AB-202 for the treatment of CLN1 disease. CLN1 disease, also known as infantile Batten disease, is caused by a mutation in the PPT1 gene. In...

May 21, 2019

Developments

Oragenics enrolls 80 patients in Phase 2 oral mucositis trial

Oragenics (NYSE American:OGEN) has enrolled more than 80 patients in its Phase 2 trial of AG013 for the treatment of oral mucositis (OM). The company also reported that the WHO provided AG013 with the generic name...

May 21, 2019

Category - Developments

Subscribe